Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Joshua Denny, Eric Dishman, Stephanie Devaney, More

NIH: Joshua Denny, Eric Dishman, Stephanie Devaney

Joshua Denny has been selected as CEO of the US National Institutes of Health's All of Us research program. He will replace Eric Dishman, who will become chief innovation officer for the program. Denny is currently a professor in the departments of Biomedical Informatics and Medicine at Vanderbilt University Medical Center. He is also the principal investigator for the All of Us Data and Research Center, and he was a member of an advisory committee to the NIH director that helped develop the All of Us program.

Stephanie Devaney, currently deputy director for the All of Us program, is being promoted to chief operating officer, a new position.

Stilla Technologies: Khaled Bahi, Jerome Leclercq, Quang Tran

Stilla Technologies has added Khaled Bahi as chief financial officer, Jerome Leclercq as senior vice president for commercial operations, Europe and Asia, and Quang Tran as quality and regulatory affairs director.

Bahi has more than 20 years of experience in the medtech industry in finance and operations roles, previously serving as CFO of the Swiss cardiovascular company Symetis, which was acquired by Boston Scientific. Leclercq has more than 30 years of experience in the commercialization of advanced technologies in the life sciences and previously held senior positions at Gilson and PerkinElmer. Tran has more than 20 years experience in the medtech and biotech industries in quality, regulatory, and operating roles, with previous positions at BioSerenity and Becton Dickinson, among others.

10x Genomics: Paul Conley

Paul Conley has resigned from 10x Genomics' board of directors, effective immediately. In a document filed with the US Securities and Exchange Commission, 10x said Conley's decision "was due solely to time commitments and a personal decision to pursue other business opportunities and is not due to any disagreement with the company's management team, operations, financial statements, policies, or procedures."

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

Filed under